2Gerdes J, Schwab U, Lemke H, et al. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation [J]. Iht J Cancer, 1983,31 (1):13-20.
3Hall PA, Levison DA, Woods AL, et al. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms [J]. J Pathol, 1990, 162(4): 285-294.
4Mullerat J, Deroide F, Winslet MC, et al. Proliferation and p53expression in anal cancer precursor lesions [J]. Anticancer Res,2003, 23 (3C): 2995-2999.
5Liu M, Lawson G, Delos M, et al. Predictive value of the fraction of cancer cells immunolabeled for proliferating cell nuclear antigen or Ki67 in biopsies of head and neck carcinomas to identify lymph node metastasis: comparison with clinical and radiologic examinations [J]. Head Neck,2003,25(4): 280-288.
6Tut VM, Braithwaite AL, Angus B, et al. Gyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53,wafl, pRb and Ki67 [J]. Br J Gancer,2001, 84(2): 270-275.
7Bhatavdekar JM, Patel DD, Shah NG,et al. Prognostic significance of immunohisto-chemically localized biomarkers in stage Ⅱ and stage Ⅲ breast cancer: a multivariate analysis [J] . Ann Surg Oncol,2000, 7 (4): 305-311.
8Vincent-Salomon A, Rousseau A, Jouve M, et al. Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy [J]. Eur J Cancer,2004(40): 1502-1508.
9Nakopoulou L, Stefanaki K, Panayotopoulou E, et al. Expression of the vascular endothelial growth factor receptor-2/Flk-1 in breast carcinomas: correlation with proliferation [J]. Hum Pathol,2002,33(9): 863-870.
10Norberg T, Klaar S, Kaff G, et al. Increased p53 nutation frequency during tumor progression-results from a breast cancer cohort [J]. Cancer Res, 2001, 61 (22): 8317-8321.
